111

The company, positioned at the crossroads of the booming Chinese healthcare and e-commerce markets, is primarily focusing on the growth of its direct B2C online drug store, 111.com.cn, which sells both drugs (OTC and prescribed medicine) and a large range of health-related products (lenses, vitamins, supplements, medical equipment, etc.). In addition, New Peak is building B2B online platforms to allow hospitals and pharmacies to directly buy medicines from pharma manufacturers, and therefore reduce the number of intermediaries in China’s drug-sourcing chain.

New Peak is also engaged in the development of an innovative consumer health service portal named Yizhen, which offers remote doctor diagnosis together with extensive drug and medicine information / recommendations.

The founders’ ultimate vision is to enable hundreds of millions of Chinese consumers to get access to higher-quality and more reliable medical services, including more affordable drugs. Verlinvest first invested in the business in December 2014.